Wird geladen...
Secukinumab: A Review in Psoriatic Arthritis
Secukinumab (Cosentyx(®)) is a fully human monoclonal antibody that selectively targets interleukin (IL)-17A, a proinflammatory cytokine involved in the pathogenesis of psoriatic arthritis (PsA). Administered subcutaneously, the first-in-class anti-IL-17 agent is approved in numerous countries world...
Gespeichert in:
| Veröffentlicht in: | Drugs |
|---|---|
| 1. Verfasser: | |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Springer International Publishing
2021
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8049904/ https://ncbi.nlm.nih.gov/pubmed/33661486 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-021-01476-3 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|